Login to Your Account


Uni-Bio's osteoporosis candidate achieves phase III endpoint

By Shannon Ellis
Staff Writer

Thursday, July 3, 2014
SHANGHAI – Hong Kong-based Uni-Bio Science Group Ltd. (HKSE:690) said Uni-PTH, an anabolic agent that builds bone mass in post-menopausal women suffering from osteoporosis, has achieved its primary endpoint in a phase III trial. Uni-PTH could be considered a biosimilar of Forteo (teriparatide, Eli Lilly and Co.). But since China has no pathway to prove biosimilarity, Uni-Bio took the drug through its paces as if it were a new drug.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription